Receptor affinities Receptor Ki (nM) 5-HT2A Dopamine receptor D1 Serotonin transporter Dopamine receptor D2 Dopamine receptor D4 Alpha-1A adrenergic receptor Alpha-1B adrenergic receptor Mechanism of action<unk>  acts as an antagonist of 5-HT2A receptor and antagonizes several dopamine receptor subtypes (D1, D2, and D4). It has moderate serotonin transporter reuptake inhibition. It has additional off-target antagonism at alpha-1 receptors, without appreciable antimuscarinic or antihistaminergic properties. Pharmacokinetics After taking the medication by mouth,<unk>  reaches maximum plasma concentrations within 1–2 hours and has a terminal elimination half-life of 18 hours.<unk>  is a substrate for numerous metabolic enzymes, including various glucuronosyltransferase (UGT) isoforms (UGT1A1, 1A4, and 2B15), aldo-keto reductase (AKR) isoforms (AKR1C1, 1B10, and 1C4), and cytochrome P450 (CYP) enzymes (CYP3A4, 2C8, and 1A2).<unk>  does not cause appreciable inhibition of any common CYP450 enzymes. It is not a substrate for p-glycoprotein.
Lumateperone
Tolperisone
Buffalopox
Tesofensine
Bremazocine
Eptazocine
Cidoxepin
Clorotepine